SCHEMBL3617047

SCHEMBL3617047

CC(C)(C)[Si](C)(C)OCCNc1ccc(NC(=O)c2ccc(C#N)cc2NC(=O)c2ccc(Cl)s2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS12 P56730 3/20 0.41
KMT2A Q03164 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MAPT P10636 2/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
ALDH1A1 P00352 5/20 0.38
KDM4E B2RXH2 5/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
MEN1 O00255 3/20 0.36
CETP P11597 1/20 0.36
F10 P00742 2/20 0.36
HPGD P15428 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
TSHR P16473 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3604203 0.89 PRSS12 (0.47) PRSS12KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL3613707 0.88 PRSS12 (0.43) PRSS12KMT2ASMN1; SMN2MAPTHTT
SCHEMBL3615579 0.88 PRSS12 (0.43) PRSS12KMT2ASMN1; SMN2MAPTMAPK1
SCHEMBL3609334 0.88 PRSS12 (0.38) PRSS12KMT2ASMN1; SMN2MAPTMAPK1
SCHEMBL3611924 0.87 PRSS12 (0.41) PRSS12KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL3616983 0.87 F10 (0.47) PRSS12KMT2ASMN1; SMN2MAPTMAPK1
SCHEMBL3614368 0.87 F10 (0.44) PRSS12KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL3614270 0.86 PRSS12 (0.44) PRSS12KMT2ASMN1; SMN2MAPTHTT
SCHEMBL3622276 0.84 PRSS12 (0.42) PRSS12KMT2ASMN1; SMN2MAPTHTT
SCHEMBL3616460 0.84 PRSS12 (0.43) PRSS12KMT2ASMN1; SMN2MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004292-A1 Iminooxazolidine Derivatives and Their Use BAYER HEALTHCARE AG (DE) 2010-01-07 US disclosed
US-20100004292-A1 Iminooxazolidine Derivatives and Their Use BAYER HEALTHCARE AG (DE) 2010-01-07 US disclosed
EP-1928868-A1 IMINOOXAZOLIDINE DERIVATIVES AND USE THEREOF Bayer HealthCare AG (DE) 2008-06-11 EP disclosed
WO-2007028520-A1 IMINOOXAZOLIDINE DERIVATIVES AND USE THEREOF BAYER HEALTHCARE AG (DE) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004292-A1 Iminooxazolidine Derivatives and Their Use PPOX, XDH, PNPO PRSS12 3975/4885KMT2A 4031/4885SMN1; SMN2 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.